Thyrocare Results Analysis

, Consolidated Revenue for FY25 is Rs 687 Cr, 20% growth YoY, Franchise revenue for FY25 grew by 18% YoY, Partnership revenue excluding API for FY25 grew by 36% YoY, Active Franchisees 11,000+ increased by 16% YoY. India’s 1st and only 100% NABL Accredited national diagnostic Laboratory chain. 21% YoY Revenue growth in overall business and 78% YoY growth in Normalized EBITDA in Q4-2025. Normalized EBITDA % increased by 1,026 Basis Points primarily due to improved margin and operating leverage in Q4-2025. Net capex invested in FY25 was INR 44.9 Cr on account of infrastructure expansion and replacement of machines. Entire loan being repaid during the FY.